Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) have received an average rating of “Moderate Buy” from the eleven brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and ten have issued a buy recommendation on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $44.17.
STOK has been the topic of a number of research reports. Guggenheim reiterated a “buy” rating and set a $60.00 target price on shares of Stoke Therapeutics in a research report on Tuesday, August 4th. Chardan Capital restated a “buy” rating and issued a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. The Goldman Sachs Group restated a “buy” rating and issued a $43.00 price target on shares of Stoke Therapeutics in a report on Friday, October 30th. JPMorgan Chase & Co. started coverage on shares of Stoke Therapeutics in a research note on Friday, August 21st. They issued an “overweight” rating and a $40.00 price target for the company. Finally, Weiss Ratings lowered shares of Stoke Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th.
Get Our Latest Stock Report on Stoke Therapeutics
Stoke Therapeutics Stock Down 0.2%
NASDAQ STOK opened at $26.63 on Thursday. The business has a 50 day simple moving average of $26.39 and a 200 day simple moving average of $30.74. Stoke Therapeutics has a one year low of $22.05 and a one year high of $40.22.
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.15). The business had revenue of $11.26 million for the quarter, compared to the consensus estimate of $8.21 million. Stoke Therapeutics had a negative return on equity of 67.30% and a negative net margin of 862.07%. On average, equities analysts predict that Stoke Therapeutics will post -3.91 EPS for the current year.
Insider Activity at Stoke Therapeutics
In other news, insider Barry Ticho sold 1,051 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the transaction, the insider directly owned 19,059 shares of the company’s stock, valued at $498,583.44. This represents a 5.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 7,223 shares of company stock worth $214,068 in the last ninety days. Insiders own 9.60% of the company’s stock.
Institutional Trading of Stoke Therapeutics
Several hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Stoke Therapeutics in the second quarter worth approximately $192,307,000. Jupiter Topco LLC bought a new position in shares of Stoke Therapeutics in the second quarter valued at approximately $59,358,000. Troluce Capital Advisors LLC bought a new position in shares of Stoke Therapeutics in the first quarter valued at approximately $21,255,000. Goldman Sachs Group Inc. lifted its holdings in shares of Stoke Therapeutics by 75.5% in the third quarter. Goldman Sachs Group Inc. now owns 1,009,560 shares of the company’s stock valued at $26,249,000 after purchasing an additional 434,216 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in shares of Stoke Therapeutics by 13.7% during the second quarter. Wellington Management Group LLP now owns 3,519,301 shares of the company’s stock valued at $115,152,000 after buying an additional 423,601 shares during the last quarter.
Stoke Therapeutics Company Profile
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.
Recommended Stories
- Five stocks we like better than Stoke Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
